Conference Coverage

DANCAVAS misses primary endpoint but hints at benefit from comprehensive CV screening

Publish date: August 27, 2022

 

AT ESC CONGRESS 2022

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Does DTC heart drug advertising discourage lifestyle changes?
MDedge Endocrinology
Cholesterol levels lowering in U.S., but disparities emerge
MDedge Endocrinology
How much weight does my patient need to lose?
MDedge Endocrinology
Barcelona beckons for first hybrid ESC Congress
MDedge Endocrinology
‘Conservative’ USPSTF primary prevention statin guidance finalized
MDedge Endocrinology
NSAIDs linked to heart failure risk in diabetes
MDedge Endocrinology
Early menopause linked with increased risk of heart problems
MDedge Endocrinology
Congressman’s wife died after taking herbal remedy marketed for diabetes and weight loss
MDedge Endocrinology
Secondary CV prevention benefit from polypill promises global health benefit
MDedge Endocrinology
Dapagliflozin’s HFpEF benefit recasts heart failure treatment: DELIVER
MDedge Endocrinology